Humanwell Healthcare (600079.SH): Midazolam Injection has received marketing authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA).

Humanwell Healthcare (600079.SH) announced that its holding subsidiary, Yichang Renfu Pharmaceutical Co., Ltd. (referred to as "Yichang Renfu," in which the company holds an 80% stake), has received the marketing authorization approval letter for midazolam injection issued by the UK Medicines and Healthcare products Regulatory Agency (MHRA). Midazolam injection has been granted marketing authorization by the UK Medicines and Healthcare products Regulatory Agency (MHRA), with the approved indications as follows: (1) for conscious sedation before, during, and after diagnostic or therapeutic procedures (with or without the use of local anesthesia); (2) as a premedication before anesthesia induction in adults, for anesthesia induction, and in combination with other anesthetics as a sedative; premedication before anesthesia induction in children; (3) for sedation in the intensive care unit (ICU).